Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis
– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases
– Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression
– Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience
